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Cellular mechanisms have been proposed in the pathogenesis of fibrotic 
processes in kidney.  In this setting, cell sources underlying the generation of matrix-
producing cells in diseased kidneys have been categorized as activated resident 
stromal cells (e.g., fibroblasts, pericytes), infiltrating bone marrow-derived cells (e.g., 
fibrocytes, T cells, macrophages), cells derived from epiethelial-mesenchymal 
transition/endothelial-mesenchymal transition.  Among these cell sources, 
accumulating evidence has shed light on the involvement of bone marrow-derived 
cells including monocytes/macrophages and a circulating mesenchymal progenitor 
cell, fibrocyte, in the progression of fibrosis in kidney.  Bone marrow-derived cells 
positive for CD45 or CD34, and type I (pro)collagen dependent on chemokine system 
and renin-angiotensin system migrate into diseased kidneys and enhance the 
synthesis matrix protein, cytokines/chemokines and pro-fibrotic growth factors, 
which may promote and escalate chronic inflammatory processes and possible 






Fibrosis is a characteristic hallmark that determines the prognosis of any kind of 
progressive kidney diseases, leading to kidney failure.  The histological characteristics 
of interstitial fibrosis in kidney are evidenced by the presence of tubular atrophy and 
dilation, interstitial leukocyte infiltration, accumulation of fibroblasts, and increased 
interstitial matrix deposition (1). In this aspect, there is accumulating evidence that 
cellular mechanisms driving fibrosis are involved (2). Cell sources underlying the 
generation of matrix-producing cells in diseased kidneys have been categorized as 
follows; 1) Activated resident stromal cells (e.g., fibroblasts, pericytes), 2) infiltrating 
bone marrow-derived cells (e.g. fibrocytes, T cells, macrophages), 3) epithelial-
mesenchymal transition, EMT/endothelial-mesenchymal transition, EndMT (3-5) 
(Figure 1). 
 
Among cells responsible for kidney fibrosis, fibrocytes, originally identified as a 
circulating bone marrow-derived, CD34+ cell population of fibroblast-like cells in 1994, 
was reported to infiltrate from inflammatory exudates into subcutaneously implanted 
wound chambers (6). Accumulating evidence suggests that fibrocytes, uniquely 
comprising a minor fraction of the circulating pool of leukocytes (less than 1%), are a 
candidate for participating in organ fibrosis associated with conditions in lungs, skin and 
visceral fibrosis, heart, liver and kidneys, as well as in the physiological roles, such as 
wound repair, cochlear physiology and auditory function (7-8).  In addition, a recent 
study reveals that the delicate balance of peroxisome proliferators-activated receptor 
gamma and transforming growth factor (TGF)-beta 1 activation drives the selection of 
an adipocyte or myofibroblast differentiation pathway through SAPK/JNK signaling (9).   
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Originally, fibrocytes were identified by CD34 and collagen-1 co-expression (6, 7).  A 
recent study revealed that markers (CD45RO, 25F9, S100A8/A9) that distinguish 
monocyte-derived fibrocytes from monocytes, macrophages, and fibroblasts (10).  
However, identification of markers specific to fibrocytes remains to be investigated.  
Fibrocytes may be identified by dual positivity of CD34 or CD45 and collagen-1 or pro-
collagen-1 (6, 7).   
 
Herein, in this manuscript, we focus on the involvement of bone marrow-derived cells, 
contributing to the pathogenesis of kidney fibrosis. 
 
Detection of cells dual positive for CD34 or CD45 and type I collagen in kidney 
fibrosis 
The detection and role of fibrocytes in the progressive fibrosis in kidney remains 
investigated thus far.  We have uncovered CD45- and type I collagen-dual positive cells 
(CD45+/ColI+) infiltrated the interstitium, especially the corticomedullary regions in 
progressive kidney fibrosis induced by ureteral ligation in mice by immunostainings and 
flow cytometry analyses (11) (Figure 2a).  The number of infiltrating fibrocytes 
increased with the progression of fibrosis after a ureteral ligation, reaching a peak on day 
7 (Figure 2b).  To further verify the existence of fibrocytes, dual immunostainings of 
CD34 and type I collagen were also performed.  The infiltration of CD34- and type I 
collagen-dual positive cells was also observed in the interstitium and correlated with 
disease progression as determined by CD45- and type I collagen-dual immunostainings 
(11).   
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These findings in mice prompted us to explore the presence of CD45- and type I 
procollagen-dual positive cells (CD45+/proColI+) infiltrating into human kidneys, 
including diabetic nephropathy. The number of infiltrating CD45+/proColI+ in the 
interstitium correlated well with the severity of tubulointerstitial lesions, such as 
interstitial fibrosis, the number of CD68-positive macrophages as well as urinary 
monocyte chemoattractant protein-1 (MCP-1)/CCL2 levels in patients with chronic 
kidney disease. In particular, there was an inverse correlation between the number of 
interstitial CD45+/proColI+ and kidney function at the time of biopsy (12).   The numbers 
of interstitial CD45+/proColI+ and macrophages as well as urinary MCP-1/CCL2 levels 
were significantly decreased during convalescence induced by glucocorticoid therapy.  
Collectively, these results suggest that cells dual positive for CD34 or CD45 and type I 
(pro)collagen may be involved in the pathogenesis of chronic kidney disease, leading to 
kidney fibrosis through the interaction with macrophages as well as MCP-1/CCL2. 
 
Chemokine system involved in infiltration of bone marrow-derived cells dual 
positive for CD34 or CD45 and type I collagen into kidney  
It is of note that fibrocytes, isolated from human and mice, express chemokine receptors 
such as CCR2, CCR3, CCR5, CCR7, and CXCR4, thereby regulating the recruitment to 
sites of fibrosis (7, 11, 13-15).  Supporting this notion, intradermal instillation of 
SLC/CCL21 was firstly described to induce the recruitment of fibrocytes at the injected 
site (16).  In addition to skin lesions, CCR7-expressing infiltrating cells, also positive 
for type 1 collagen (CCR7+/ColI+), were detected in diseased kidneys 7 days after 
ureteral ligation in wild-type mice (11). 37.8% of infiltrating cells expressed CCR7 
(number of CCR7+/ColI+ divided by the number of CCR7+ or CXCR4+ or 
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CCR2+/ColI+).  In wild-type mice, the ratio of CCR7+/ColI+ in obstructed kidneys was 
increased to 7.9% of the total isolated renal cells compared with that in normal kidneys 
(0.25%) and contralateral kidneys (0.21%).  Of these CCR7-expressing cells in 
obstructed kidneys, 66.5% of cells were CXCR4+/CCR2+, 16.8% of cells were 
CXCR4+/CCR2-, 4.3% of cells were CXCR4-/CCR2+, and 12.4% of cells were CXCR4-
/CCR2.  The impact of CCL21/CCR7 signaling on progressive kidney interstitial 
fibrosis was further examined.  Mean interstitial fibrosis as well as the amount of 
hydroxyproline were reduced by almost 50 % in mice treated with anti-CCL21 
antibodies compared with that in wild-type mice 7 days after an ureteral ligation, which 
was confirmed by the similar reduction in CCR7-null mice (11).  Accordingly, based on 
the finding that treatment with anti-CCL21 antibodies or CCR7 deficiency resulted in 
over 50% reduction in the number of CD45+/ColI+, thereby CCL21/CCR7 signaling is 
thought to be the major pathway attracting CD45+/ColI+ into the kidney in this 
particular model (11).  Interestingly, blockade of CCL21/CCR7 signaling reduced the 
number CCR2-expressing infiltrates in immunohistochemical studies along with renal 
transcripts of MCP-1/CCL2. In vitro studies also revealed that stimulation of cultured 
CD45+/ColI+ with angiotensin II enhanced the expression of mRNA of type 1 collagen 
and TGF-beta (17). These findings further suggest that CD45+/ColI+ may contribute to 
kidney fibrosis by producing MCP-1/CCL2 and TGF-beta, which may be responsible 
for chronic persistent inflammatory processes and activation of resident stromal cells 
(e.g., fibroblasts, pericytes) and the process to EMT/EndMT, in addition to collagen 
synthesis of CD45+/ColI+.  All these events may orchestrates fibrotic down stream 
events, eventually resulting in kidney fibrosis (Figure 1).   
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Renin-angiotensin system and bone marrow-derived cells dual positive for CD45 
and type I collagen 
Renin-angiotensin system is one of the major pathway in the pathogenesis of fibrotic 
conditions, possibly dependent on two major distinct receptors, designated as 
angiotensin II type 1 receptor (ATR1) and angiotensin II type 2 receptor (ATR2).  We 
hypothesized that CD45+/ColI+ might contribute to kidney fibrosis dependent on the 
renin-angiotensin system.  In a murine model of kidney fibrosis, the extent of kidney 
fibrosis in AT2R deficient mice was more evident, concomitantly with the larger 
number of infiltrating CD45+/ColI+ in fibrotic kidneys (17).  Interestingly, CD45+/ColI+ 
numbers in bone marrow were also increased in mice treated with ureteral ligation, 
especially in AT2R deficient mice (Figure 2c).  In the points of therapeutic views, 
pharmacologic inhibition of AT1R reduced the degree of kidney fibrosis as well as the 
number of CD45+/ColI+ in both the kidney and the bone marrow.  Supportingly, AT1R 
inhibition decreased the angiotensin II-stimulated expression of type I collagen 
synthesis in isolated human CD45+/ColI+, while an AT2R inhibitor augmented the 
expression of mRNA of type I collagen.  These results suggest that AT1R/AT2R 
signaling may contribute to the pathogenesis of kidney fibrosis by at least two 
mechanisms: (1) by regulating the number of CD45+/ColI+ in bone marrow, and (2) by 
activation of these cells (17). 
 
Fibrocytes: possible clinical biomarker for fibrotic disease 
Clinical biomarkers for reflecting fibrogenic activity and indicating disease progression 
are required in various fields.  Moeller et al. reported that fibrocytes defined as cells 
positive for CD45 and collagen-1 were significantly elevated in patients with stable 
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idiopathic pulmonary fibrosis (IPF), with a further increase during acute disease 
exacerbation. Fibrocyte numbers were an independent predictor of early mortality. The 
mean survival of patients with fibrocytes higher than 5% of total blood leukocytes was 
7.5 months compared with 27 months for patients with less than 5%. Thus, they 
conclude that circulating fibrocytes in patients with IPF are an indicator for disease 
activity of IPF and might be useful as a clinical marker for disease progression (18).   
Supporting this notion, the number of interstitial CD45+/proColI+ was significantly 
decreased during convalescence induced by glucocorticoid therapy in patients with 
chronic kidney diseases (12).  Further studies would be required for providing the 
evidence that counting fibrocyte numbers might be a biomarker for activity and 
progression of fibrotic conditions. 
 
Involvement of monocytes/macrophages in kidney fibrosis 
Recent studies reveal that macrophage diversity in response to their microenvironment 
uncovers their roles in kidney injury, raising therapeutic possibilities to attenuate kidney 
fibrosis (19-20).  With our viewpoint, human peripheral CD14-positive 
monocytes/macrophages directly contribute to producing type I collagen, resulting in 
fibrogenesis, which are dependent on an amplification loop of MCP-1/CCL2-CCR2 
(21).   In addition, the presence of MCP-1/CCL2 expression is suggestive of a chronic 
stage of disease, especially in tubulointerstitial lesions and urinary levels of protein 
excretion, despite of renal etiologies through the recruitment and activation of 
macrophages. As is well-known, urinary protein excretion promotes and escalates 
tubulointerstitial lesions, resulting in kidney fibrosis. Moreover, the measurement of 
urinary MCP-1/CCL2 levels is a useful clinical tool for monitoring the disease activity 
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of inflammatory renal disorders, including diabetic nephropathy (22-25).  This was 
supported by the fact that blockade of MCP-1/CCL2 prevented leukocyte migration to 
the kidney, urinary protein excretion and TGF-beta expression, thereby preventing 
glomerulosclerosis and interstitial fibrosis (23, 26-28).  In addition to MCP-1/CCL2-
CCR2, blockade of fractalkine-CX3CR1 also reduced kidney fibrosis, which was 
concomitant with reduction in macrophage infiltration (29). CCR2 receptor is expressed 
in glomerular podocytes, suggesting MCP-1/CCL2 activation of CCR2 on podocytes 
may underlie induction of MMP-12, leading to glomerular basement membrane damage 
and urinary protein excretion (30).  Finally, it is of note that there were significant 
correlations between the numbers of CD45+/proColI+ and macrophages in human 
kidneys as well as urinary levels of MCP-1/CCL2, suggesting the close relationship of 
CD45+/proColI+ with macrophages.  Based on these results, we propose MCP-1/CCL2-
CCR2 axis on the recruitment and activation of bone marrow-derived cells, especially 
macrophages, play a role in the pathogenesis of tubulointerstitial lesions, resulting in 
kidney fibrosis despite of kidney etiologies (Figure 3).   
 
Involvement of T cells in kidney fibrosis 
The degree of fibrosis is related to leukocyte infiltration.  Tapmeier et al. examined the 
role of different T cell populations on kidney fibrosis in the mouse model of unilateral 
ureteral obstruction (31).  They found a critical role for CD4+ T cells in kidney fibrosis.  
In addition, Nikolic-Paterson describes modulation of T cells in the process of kidney 
fibrosis; 1) T cells may act directly fibroblasts and pericytes to promote their migration, 
proliferation, and differentiation, resulting in the accumulation of alpha-SMA+ 
myofibroblasts, which synthesize and deposit interstitial matrix, 2) T cells may induce a 
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profibrotic phenotype in the infiltrating macrophage population, which, in turn, secrete 
pro-fibrotic and pro-proliferative cytokines and growth factors that induce fibroblast 
migration, proliferation, and differentiation, 3) T cells may act directly on tubular 
epithelial cells to induce secretion of cytokines and growth factors that, in turn, act on 
fibroblasts (32). 
 
Stromal cell activation and myofibroblast generation in kidney fibrosis 
Activation of local stromal cells (e.g., fibroblasts and pericytes) and generation of 
myofibroblasts from epithelial cells (via EMT), pericytes, endothelial cells (via 
EndMT) and bone marrow-derived cells are key processes in tubulointerstitial fibrosis 
(33).  For 15 years, EMT has been viewed as a principle source of fibroblasts in tissue 
fibrosis (34).  In addition to tubular epithelial cells, glomerular podocytes (35) and 
endothelial cells (36-37) undergo transition after injury, which have been reported to be 
involved in kidney damage, resulting in fibrosis.  More recently, in the process of 
perpetuation of fibrogenensis, hypermethylation of RASAL1, encoding an inhibitor of 
the Ras oncoprotein, is associated with the perpetuation of fibroblast activation and 
fibrogenesis in the kidney (38). In contrast, Duffiels et al. describe that pericytes and 
perivascular fibroblasts are primary source of collagen-producing cells in kidney 
fibrosis (39-40).  Therefore, further studies would be required for determining the 
degree to which processes including those resulted from bone marrow-derived cells, 
contributes to kidney fibrosis. 
 
Concluding remarks and future directions 
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A deep insight of bone marrow-derived cells dependent on chemokine system and 
renin-angiotensin system provides a key for the novel pathogenesis of progressive organ 
fibrosis including kidney fibrosis.  In addition to those systems, our recent unpublished 
data suggest the possible involvement of CD45+/ColI+ in diabetic nephropathy, which is 
supported by the evidence that CD45+/proColI+ are detected in human diabetic 
nephropathy (12).  Further studies for biology of bone marrow-derived cells and the 
interaction of resident stromal cells would be required for a better understanding and the 
therapeutic benefit for kidney fibrosis. 
 
Acknowledgements 
 TW is a recipient of a Grant-in-Aid from the Ministry of Education, Science, 
Sports and Culture in Japan and Takeda Science Foundation.   
 
References 
1. Strutz F, Zeisberg M. Renal fibroblasts and myofibroblasts in chronic kidney disease.  
J Am Soc Nephrol. 2006; 17, 2992-2998. 
2. Wynn TA.  Cellular and molecular mechanisms of fibrosis.  J Pathol. 2008; 214, 199-
210. 
3. Guarino M, Tosoni A, Nebuloni M. Direct contribution of epithelium to organ 
fibrosis: epithelial-mesnchymal transition.  Hum Pathol 2009; 40, 1365-1376. 
4. Vernon MA, Mylonas K, Hughes J. Macrophages and renal fibrosis. Semn Nephrol. 
2010; 30, 302-307. 
 12
5. Tapmeier TT, Fearn A, Brown K, Chowdhury P, Sacks SH, Sheerin NS, Wong W. 
Pivotal role of CD4+ T cells in renal fibrosis following ureteric obstruction.  Kidney 
Int.  2010; 78, 351-362. 
6. Bucala R, Spiegel L, Chesney J, Hogan M, Cerami A. Circulating fibrocytes define a 
new leukocyte subpopulation that mediates tissue repair. Mol Med 1994; 1, 71-81. 
7. Herzog EL, Bucala R. Fibrocytes in health and disease. Exp Hematol. 2010; 38, 548-
556. 
8. Delprat B, Ruel J, Guitton MJ, Hamard G, Lenior M, Pujol R, Puel JL, Brabet P, 
Hamel CP. Deafness and cochlear fibrocyte alterations in mice deficient for the inner 
ear protein otospiralin. Mol Cell Biol. 2005; 25, 847-853. 
9. Hong KM, Belperio JA, Keane MP, Burdick MD, Strieter RM.  Differentiation of 
human circulating fibrocytes as mediated by transforming growth factor-beta and 
peroxisome proliferators-activated receptor gamma.  J Biol Chem. 2007; 282, 22910-
22920. 
10. Pilling D, Fan T, Huang D, Kaul B, Gomer RH.  Identification of markers that 
distinguish monocyte-derived fibrocytes from monocytes, macrophages, and fibroblasts.  
PLoS One 2009; 4, e7475. 
11. Sakai N, Wada T, Yokoyama H, Lipps M, Ueha S, Matsushima K, Kaneko S. 
Secondary lymphoid tissue chemokine (SLC/CCL21)/CCR7 signaling regulates 
fibrocytes in renal fibrosis. Proc Natl Acad Sci USA. 2006; 103, 14098-14103. 
12. Sakai N, Furuichi K, Shinozaki Y, Yamauchi H, Toyama T, Kitajima S, Okumura 
T, Kokubo S, Kobayashi M, Takasawa K, Takeda S, Yoshimura M, Kaneko S, Wada 
T.Fibrocytes are involved in the pathogenesis of human chronic kidney disease.  Human 
Pathol. 2010; 41, 672-678. 
 13
13. Moore BB, Kolodsick JE, Thannickal VJ, Cooke K, Moore TA, Hogaboam C, 
Wilke CA, Toews GB. CCR2-mediated recruitment of fibrocytes to the alveolar space 
after fibrotic injury. Am J Pathol. 2005; 166, 675-684. 
14. Phillips RJ, Burdick MD, Hong K, Lutz MA, Murray LA, Xue YY, Belperio JA, 
Keane MP, Strieter RM. Circulating fibrocytes traffic to the lungs in response to 
CXCL12 and mediate fibrosis.  J Clin Invest. 2004; 114, 438-446. 
15. Ishida Y, Kimura A, Kondo T, Hayashi T, Ueno M, Takakura N, Matsushima K, 
Mukaida N. Essential roles of the CC chemokine ligand 3-CC chemokine receptor 5 
axis in bleomycin-induced pulmonary fibrosis through regulation of macrophage and 
fibrocyte infiltration. Am J Pathol. 2007; 170, 843-854. 
16. Abe R, Donnelly SC, Peng T, Bulaca R, Metz CN. Peripheral blood fibrocytes: 
Differentiation pathway and migration to wound sites. J Immunol. 2001; 166: 7556-
7562. 
17. Sakai N, Wada T, Iwai M, Horiuchi M, Matsushima K, Kaneko S. The renin-
angiotensin system contributes to renal fibrosis through regulation of fibrocytes. J 
Hypertens. 2008; 26, 780-790. 
18. Moeller A, Gilpin SE, Ask K, Cox G, Cook D, Gauldie J, Margetts PJ, Farkas L, 
Dobranowski J, Boylan C, O'Byrne PM, Strieter RM, Kolb M. Circulating fibrocytes 
are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit 
Care Med. 2009; 79, 588-594. 
19. Ricardo SD, van Goor H, Eddy AA. Macrophage diversity in renal injury and 
repair. J Clin Invest. 2008;118, 3522-3530. 
20. Ninichunk V, Anders HJ. Bone marrow-derived progenitor cells and renal fibrosis. 
Front Biosci. 2008; 13, 5163-5167. 
 14
21. Sakai N, Wada T, Furuichi K, Shimizu K, Kokubo S, Hara A, Yamahana J, 
Okumura T, Matsushima K, Yokoyama H, Kaneko S. MCP-1/CCR2-dependent loop for 
fibrogenesis in human peripheral CD14-positive monocytes. J Leukoc Biol. 2006; 79, 
555-563. 
22. Wada T, Yokoyama H, Su SB, Mukaida N, Iwano M, Dohi K, Takahashi Y, Sasaki 
T, Furuichi K, Segawa, C, Hisada Y, Ohta S, Takasawa K, Kobayashi K, Matsushima 
K. Monitoring urinary levels of monocyte chemotactic and activating factor reflects 
disease activity of lupus nephritis.  Kidney Int.  1996; 49, 761-767. 
23. Wada T, Yokoyama H, Furuichi K, Kobayashi K, Harada K, Naruto M, Su SB, 
Akiyama, M, Mukaida N, Matsushima. Intervention of crescentic glomerulonephritis by 
antibodies to monocyte chemotactic and activating factor (MCAF/MCP-1).  FASEB J. 
1996; 10, 1418-1425. 
24. Wada T, Furuichi K, Segawa C, Shimizu M, Sakai N, Takeda S, Takasawa K, Kida 
H, Kobayashi, K, Mukaida N, Ohmoto Y, Matsushima K, Yokoyama H. MIP-1 and 
MCP-1 contribute crescents and interstitial lesions in human crescentic 
glomerulonephritis. Kidney Int.  1999; 56, 995-1003. 
25. Wada T, Furuichi K, Sakai N, Iwata Y, Yoshimoto K, Shimizu M, Takeda S, 
Takasawa K, Yoshimura M, Kida H, Kobayashi KI, Mukaida N, Naito T, Matsushima 
K, Yokoyama H. Up-regulation of monocyte chemoattractant protein-1 in 
tubulointerstitial lesions of human diabetic nephropathy. Kidney Int 2000; 58, 1492-
1498. 
 15
26. Wu X, Dolecki GJ, Sherry B, Zagorski J, Lefkowith JB. Chemokines are expressed 
in a myeloid cell-dependent fashion and mediate distinct functions in immune complex 
glomerulonephritis in rat. J Immunol. 1997; 158,3917-3924. 
27. Wada T, Furuichi K, Sakai N, Iwata Y, Kitagawa K, Ishida Y, Kondo T, 
Hashimoto H, Ishiwata Y, Mukaida N, Tomosugi N, Matsushima K, Egashira K, 
Yokoyama H. Gene therapy via blockade of monocyte chemoattractant protein-1 for 
renal fibrosis. J Am Soc Nephrol. 2004;15, 940-948. 
28. Kitagawa K, Wada T, Furuichi K, Hashimoto H, Ishiwata Y, Asano M, Takeya M, 
Kuziel WA, Matsushima K, Mukaida N, Yokoyama H. Blockade of CCR2 ameliorates 
progressive fibrosis in kidney. Am J Pathol. 2004;165, 237-246. 
29. Furuichi K, Gao JL, Murphy PM. Chemokine receptor CX3CR1 regulates renal 
interstitial fibrosis after ischemia-reperfusion injury. Am J Pathol. 2006;169, 372-387. 
30. Rao VH, Meehan DT, Delimont D, Nakajima M, Wada T, Gratton MA, Cosgrove 
D. Role for macrophage metalloelastase in glomerular basement membrane damage 
associated with alport syndrome. Am J Pathol. 2006;169, 32-46. 
31. Tapmeier TT, Fearn A, Brown K, Chowdhury P, Sacks SH, Sheerin NS, Wong W. 
Pivotal role of CD4+ T cells in renal fibrosis following ureteric obstruction. Kidney Int. 
2010;78, 351-362. 
32. Nikolic-Paterson DJ. CD4+ T cells: a potential player in renal fibrosis. Kidney Int. 
2010;78, 333-335. 
33. Grande MT, López-Novoa JM. Fibroblast activation and myofibroblast generation 
in obstructive nephropathy. Nat Rev Nephrol. 2009;5, 319-328. 
34. Zeisberg M, Duffield JS. Resolved: EMT produces fibroblasts in the kidney. J Am 
Soc Nephrol. 2010;21, 1247-1253. 
 16
35. Liu Y. New insights into epithelial-mesenchymal transition in kidney fibrosis.  J 
Am Soc Nephrol. 2010; 21, 212-222. 
36. Li J, Qu X, Bertram JF. Endothelial-myofibroblast transition contributes to the early 
development of diabetic renal interstitial fibrosis in streptozotocin-induced diabetic 
mice. Am J Pathol. 2009;175, 1380-1388. 
37. Kizu A, Medici D, Kalluri R. Endothelial-mesenchymal transition as a novel 
mechanism for generating myofibroblasts during diabetic nephropathy.  Am J Pathol. 
2009; 175, 371-373. 
38. Bechtel W, McGoohan S, Zeisberg EM, Müller GA, Kalbacher H, Salant DJ, Müller 
CA, Kalluri R, Zeisberg M. Methylation determines fibroblast activation and 
fibrogenesis in the kidney. Nat Med. 2010;16, 544-550.  
39. Humphreys BD, Lin SL, Kobayashi A, Hudson TE, Nowlin BT, Bonventre JV, 
Valerius MT, McMahon AP, Duffield JS. Fate tracing reveals the pericyte and not 
epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol. 2010;176, 85-97. 
40. Lin SL, Kisseleva T, Brenner DA, Duffield JS. Pericytes and perivascular 
fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of 




Figure 1.  Possible cellular mechanims involved in fibrosis in kidney 
 
Figure 2. Cells dual positive for CD34 or CD45 and type I collagen, detected in kidneys 
and bone marrow, may play a role in kidney fibrosis. 
(a) In wild-type mice, CD45+/ColI+ infiltrated the 
Interstitium, especially the corticomedullary regions after ureteral ligation. (b) The 
number of infiltrating CD45+/ColI+ as well as mean interstitial fibrosis in kidney were 
reduced in mice treated with anti-CCL21 antibodies and in CCR7-null mice compared 
with that in wild-type mice 7 days after ureteral ligation. Values are the mean ±SEM. 
(c) By flow cytometry analyses, fibrocytes increased in number at bone marrow cells, 
which was enhanced in AT2R-null mice with ureteral ligation. 
 
Figure 3.  Macrophages dependent on MCP-1/CCL2-CCR2 axis contribute to 
progressive kidney diseases, resulting in fibrosis. 
 
